A.L. Medi-Market LTD,

Antimetabolite (pyrimidine analog). Azacitidine 100 mg.
VIAL:Pwder for susp. for inj./inf. 1 X 100 mg
 First cycle:75 mg/m² SC or IV, daily for 7 days.
Subsequent Cycles: Repeat cycles every 4 weeks. Dose may be incr. to 100 mg/m² if no beneficial effect is seen after 2 cycles. It is recomm. that pts be treated for a min. of 4 to 6 cycles. See full prescript. info.
 For pts with the following FAB myelodysplastic syndr. subtypes: refractory anemia or refractory anemia with ringed sideroblasts ( if accompanied by neutropenia or thrombocytopenia or requiring transfusions),refractory anaemia with excess blasts, refractory anaemia with excess blasts in transformation, and chronic myelomonocytic leukaemia.
C/I:Hypersens. Adv. malignant hepatic tumors.

Lincosamide. Clindamycin Phosphate 150 mg/ml.
Vial: sol for inject / infus  10 X 2 ml/4ml
To be diluted prior to IV admin. and infused over at least 10-60 minutes.
Adlts: Serious infect.: 600 mg - 1.2 g/d in 2/3/4 equal doses.
More sev. infect.: 1.2-2.7 g/d in 2/3/4 equal doses.
Single IM inject. of more than 600 mg are not recomm. nor is admin. of more than 1.2 g in a sgle one-hour infus.
For more serious infect., these doses may have to be incr. In life-threatening situations, doses as high as 4.8 g/d have been given IV to adlts.
Alternatively, may be admin. in the form of a sgle rapid infus. of the first dose followed by continuous IV infus.
Paed. pop:. Childr > 1 month of age): Serious infect: 15-25 mg/kg/d in 3 or 4 equal doses. To be dosed based on total BW regardless of obesity.
More sev. infect.: 25-40 mg/kg/d in 3 or 4 equal doses. In sev. infect. it is recommen. that childr. be given no less than 300 mg/d regardless of BW.
For the tmt.of infections caused by susceptible anaerobic bacteria.
Clindamycin does not penetrate the blood/brain barrier in therapeut. effective qtities
C/I: Hypersens. incl. to lincomycin.

PPI. Esomeprazole 40 mg.
Vial. Powd. for infus./inject. 50X 40 mg
Adults:20-40 mg 1 X dly. Transfer to oral ther. asap.  GERD with esophagitis: 40 mg 1 X dly. Sympt. tmt. GERD: 20 mg 1 X dly. All as IV, as altern. to oral ther. when oral intake not appropr. Prevent. of rebleed. follow. therap. endoscopy for acute bleed. gastric/duoden. ulcers: 80 mg as a bolus, contin. by 8 mg/h given over 3 days.
Chldr. aged 1-11: 10 mg 1 X dly. Chldr. aged 12-18: 20 mg 1X dly. See prescr. info.
 In  adlts. for: Gastroesophageal reflux disease (GERD) in pts. with esophagitis and/or sev. sympt. of reflux as an altern. to oral ther. when oral intake is not appropr / Prevent. of rebleed. follow therap. endoscopy for ac. bleeding gastric or duodenal ulcers.
In child. and adolesc. aged 1-18 years for:  Gastric antisecret. tmt. when oral route is not possible, such as GERD in pts. with erosive reflux esophagitis and/or sev. sympt. of reflux.  
C/I:  :  hypersens. to esomeprazole, substit. benzimidazoles or any other constit. Not to be administr. with nelfinavir

Estrogen Receptor Antagonist. Fulvestrant 250 mg.
Pre-filled sir. with sol. for IM inj. 2 X 250 mg/5ml
Adult females: 2 inj. admin. consecutively, one in each buttock. Repeat after 2 weeks.
Tmt. of oestrogen receptor positive, locally advanced or metastat. breast cancer in postmenopausal women: * not previously treated with endocr. ther., or * with dis. relapse on or after adjuvant endocr. ther.; or * with dis. progress. on endocr. ther.

Combin. ther. for the tmt. of: - HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in men and postmenopausal women in combin. with ribociclib as initial endocr. based ther. or following dis. progress. on endocr. ther. - HR- positive, human epidermal growth factor receptor 2 (HER2)-neg. advanced or metastatic breast cancer in combin. with palbociclib or abemaciclib in women with dis. progress. after endocr. ther.
C/I:Hypersens. Pregn. and lactat. Sev. hepatic impairm.

Benzodiazepine. Lorazepam 4 mg/ml.
Amp., sol. 1 ml X5/10 for IM and IV inj.
 Premedication
For a max. beneficial effect, dose should be calc. based on BW (usual dose is 2-4 mg) and admin. as follows:
a) I.V. admin.
For an optimal effect, doses of 0.044 mg / kg to a max of 2 mg should be used, 15-20 minutes before the procedure.
This dose (I.V. admin) will be adeq. for sedation of most adult pts and should not normally be exceeded in pats > 50 years.
Higher doses, up to 0.05 mg / kg with a max of 4 mg, can be admin.
The necessary airway equip. must be available immediately prior to the IV admin.
b) I.M. admin:
optimal effect is reached by admin. 0.05mg/kg to a max. 4mg, with min. 2 hours before the procedure. Dose is indiv. adjusted.
In case of local anesthesia and in diagn. procedures requiring ptt involvement, simultaneous use of an analgesic may be appropriate.
The dose should be reduced in case of concom. admin. of central nervous system depressants.
This drug should not be mixed with other drugs in the same syr.
Sympt. tmt. of pathological anxiety and tension in pts who, for some reason, are unable to take oral medication.
Recommended initial dose is 2-4 mg I.V. or 0.05 mg / kg I.M. (IV admin. is preferred).  If necessary, dose may be repeated after 2 hours. As soon as the acute symptomat. is controlled, the pttt must receive appropriate tmt for the underlying condition. The use of lorazepam tablets may be considered if further tmt. with benzodiazepines is required.
Status epilepticus
Adults: 4 mg IV.
Elderly: The elderly may respond to lower doses; thus, half the normal adult dose may be sufficient.
Pediatric population (age  >1 month): 0.1 mg/kg BW intravenously. Maximum 4 mg/dose

In adults and adolescents > 12 years::
As premedication, before surgical procedures or prior to diagn. procedures.
For symptom. treatment of pathological anxiety and tension in pts who, for some reason, are unable to take oral medic..
in adults, adolescents, children and infants from 1 month of age: for the control of status epilepticus.
C/I: Hypersens incl to benzodiazepines./ not to be admin. intra-arterially. As with other injectable benzodiazepines, an intra-arterial injection may cause arterial spasm that causes gangrene and may require amputation. Contraindic. in pts with:
sleep apnoea syndrome;/ sev. respir. insuff;/ myasthenia gravis;/
sev. hepatic insuff.
In childr < 12 years, except in the control of status epilepticus

Electrolyte Solutions. Magnesium Sulfate 500 mg/ml.
Amp. 10 X 2  ml or 10 ml
dosage according to indication. See full prescription info.
Tmt. of Magnesium deficiency in hypomagnesaemia, prevention and tmt of hypomagnesaemia in pts receiving total parenteral nutrition, control and prevention of seizures in severe pre-eclampsia,  control and prevention of recurrent seizures in eclampsia
C/I: Hypersens/. Hepatic encephalopathy/ hepatic failure/
Sev renal impairm. (glomerular filtr. rate under 25 ml/h)/ renal fail./ anuria/
Parenteral admin. of the medicinal product is contraindic. in pts with heart block (class I-III) or myocardial damage and myasthenia gravis